Compare Ascendis Pharma A/S (ASND) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Annaly Capital Management, Inc. — how do they compare? Ascendis Pharma A/S trades at $255.66 (market cap $16.67B), while Annaly Capital Management, Inc. trades at $23.24 (market cap $17.44B). The key difference: Ascendis Pharma A/S and Annaly Capital Management, Inc. are close in size by market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NLY | |
|---|---|---|
Market Cap | $16.67B | $17.44B |
Sector | Health | Financials |
52-Week High | $277.18 | $24.40 |
52-Week Low | $189.74 | $20.21 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
NLY trades at $22.91, down 0.56% today, with strong technical momentum showing a bullish moving average signal. The stock demonstrates robust fundamentals with a P/E of 5.59, ROE of 20.66%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with $0.79 EPS versus $0.75 estimate, supported by growing net interest income and dividend coverage improvements.
Analyst consensus remains positive with a $24.50 price target and 57% buy ratings, though investors should monitor interest rate sensitivity given the REIT's mortgage-focused business model. The 13%+ dividend yield provides income appeal, but funding costs and mortgage market volatility present ongoing risks to book value stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
